Cargando…
The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma
BACKGROUND: Gallbladder cancer is the most common billiary tract malignancy and carries a very poor prognosis. Somatostatin was recently shown to play an important role in the development of various tumors. In the current study, we evaluated the effect of doxorubicin on the chemosensitivity of gallb...
Autores principales: | Li, Ji-Yu, Quan, Zhi-Wei, Zhang, Qiang, Liu, Jian-Wen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931603/ https://www.ncbi.nlm.nih.gov/pubmed/17617924 http://dx.doi.org/10.1186/1471-2407-7-125 |
Ejemplares similares
-
C(60) Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment
por: Prylutska, Svitlana, et al.
Publicado: (2014) -
A case of gallbladder neuroendocrine carcinoma diagnosed preoperatively using somatostatin receptor scintigraphy
por: Kamikihara, Yusuke, et al.
Publicado: (2020) -
Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells
por: Wu, Di, et al.
Publicado: (2019) -
Somatostatin-Expressing Inhibitory Interneurons in Cortical Circuits
por: Yavorska, Iryna, et al.
Publicado: (2016) -
The inhibitory effect of somatostatin on gastric motility in Suncus
murinus
por: Sekiya, Haruka, et al.
Publicado: (2021)